Chemical GMP Synthesis Facility Director, Christopher Lincoln, Ph.D., received his B.S. degree from Boston University and Ph.D. degree from Oregon State University in synthetic organic chemistry. He completed postdoctoral work at the Roskamp Institute in Sarasota, Fla.
As the former head of medicinal chemistry for Archer Pharmaceuticals, he has extensive experience in process development and cGMP manufacturing. While at Archer, he developed and completed the phase I GMP synthesis of a novel therapeutic for the treatment of Alzheimer’s disease in support of both IND and IMPD submissions. This manufacturing project involved the optimization and scale up of a multistep synthetic process from the R&D laboratories to the cGMP laboratories, while increasing overall purity of the final API to >99.5%.
Lincoln was instrumental in the design of the Chemical GMP Synthesis Facility at City of Hope. He oversees all process development work related to GLP and GMP projects and plays a key role in translating basic therapeutic research to the patient care arena.